Vulvar Relaxation Syndrome
Conditions
Interventions
Platelet-rich plasma (PRP) group:The injection sites are the anterior vaginal wall, the posterior vaginal wall, and the top of the vagina, using a multi-point injection technique. Each patient receive
Laser Group:1) Apply epinumbing ointment to the vulva: thickness 2-3mm, plastic wrap for 30-40 minutes
2) Install a straight-haired pixel wristband (9X9/7X7) and a yellow visco, and connect a white blowpipe
3) Cleaning anesthetic and disinfection of the vulva
4) The operator wears laser protective glasses, fully inserts the probe into the tip of the vagina, and emits the laser at an energy density of 10 mJ and a spot density of 10–15%. After the probe is r
5) Subsequently, the probe steps back one degree from the mark on the probe body and repeats the above process. A total of 3–4 laser scans were performed throughout the vagina. 6) Tightening treatment
A small crust will form within 24 hours after treatment, allowing it to fall off naturally and cannot be artificially peeled
Cannot share a room for 3 days. Treatment course: 3 sessions/session, 4 weeks apart.
Sponsors
West China Second Hospital of Sichuan University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1.Patients with a confirmed clinical diagnosis of VRS, following the diagnostic criteria outlined in the Guidelines for the Diagnosis and Treatment of Female Vaginal Laxity. 2.No relevant treatment received in the past two weeks. 3.Complete clinical data and follow-up compliance. 4.Willingness to participate in the study and signed informed consent.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1.History of protein allergy. 2.Acute inflammatory phase of the genitourinary system. 3.Presence of hematologic disorders, immune dysfunction, or malignancies. 4.Pregnancy. 5.Severe systemic medical conditions affecting daily life (e.g., diagnosed severe cardiovascular diseases or immune system disorders). 6.Psychological or psychiatric disorders (e.g., depression) that prevent completion of follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CVFSFI score;vaginal laxity questionnaire (VLQ) score;Vaginal Health Index score; | — |
Secondary
| Measure | Time frame |
|---|---|
| sexual satisfaction questionnaire (SSQ) score;Treatment satisfaction;Pelvic floor muscle electromyography (EMG) values;Adverse events; | — |
Countries
China
Contacts
Public ContactWei Dongmei
West China Second Hospital of Sichuan University
Outcome results
None listed